# HEMP Act Industry Reactions: ‘No One Will Grow a Crop That Might Be Illegal in November’ > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/hemp-act-industry-reactions-2026-crop-legality/ > **Published:** 2026-02-23T12:53:51-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:15:02-04:00 > **Clinical Summary:** Explore hemp act industry reactions and the impact on 2026 crop legality. Stakeholders emphasize consumer safety and regulatory clarity for hemp farmers. --- CED Clinical Relevance #15 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyHempCBDIndustry Why This Matters Hemp farmers must decide right now what to plant for 2026, but nobody can tell them whether their crop will be legal by the time it’s harvested in November. Clinical Summary Industry stakeholders weigh in on the HEMP Act. AHPA President Graham Rigby calls it a ‘starting point’ that must prioritize [consumer safety](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) through rigorous scientific assessment. Jonathan Miller of the US Hemp Roundtable warns that without an extension, there will be ‘tremendous disruption up and down the food chain, particularly for farmers.’ Planting decisions for 2026 must be made well before regulatory outcomes are known. The 50-state patchwork continues causing confusion. Dr. Caplan’s Take “Asking a farmer to invest an entire growing season in a crop that Congress might criminalize before harvest isn’t a policy gap, it’s a moral failing.” Clinical Perspective ANCIENT ENZYMES, MODERN MEDICINE: WHAT WAGENINGEN’S CANNABIS DISCOVERY MEANS Researchers at Wageningen University published a breakthrough in Nature that reframes our understanding of cannabis biochemistry. They identified ancestral enzymes in cannabis that produce CBC (cannabichromene)—a cannabinoid most consumers have never heard of—as potentially the plant’s original cannabinoid. The implications are significant. Modern cannabis has been bred almost exclusively for THC and CBD production. But the evolutionary history of the plant suggests CBC and other [minor cannabinoids](https://cedclinic.com/cbd-vs-thc-vs-cbg-vs-cbn-vs-thcv-differences/) were the primary output for millions of years. These ancestral pathways were suppressed by selective breeding, not eliminated. The team used molecular phylogenetics to reconstruct the evolutionary history of cannabinoid synthase enzymes, demonstrating that the CBC pathway predates both THCA and CBDA synthesis. In practical terms, this means the enzymes that produce CBC are more genetically stable and potentially more efficient. For the cannabinoid industry, this opens a door: if CBC production can be optimized using these ancestral enzymes—whether in planta or via biosynthesis—it could unlock commercial-scale production of a cannabinoid with documented anti-inflammatory, analgesic, and neuroprotective properties. This is the kind of research that reminds us why the regulatory debate matters. Without legal clarity, American researchers and companies can’t capitalize on discoveries like this. The science is advancing. The law is retreating. Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+HEMP+Act+Industry+Reactions%3A+%27No+One+Will+Grow+a+Crop+That+Might+Be+Illegal+in+November%27+%40drcaplan&url=https%3A%2F%2Fwww.nutraingredients.com%2FArticle%2F2026%2F02%2F02%2Fproposed-hemp-act-would-create-federal-cbd-pathway-as-hemp-industry-faces-regulatory-crossroads%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.nutraingredients.com%2FArticle%2F2026%2F02%2F02%2Fproposed-hemp-act-would-create-federal-cbd-pathway-as-hemp-industry-faces-regulatory-crossroads%2F) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+HEMP+Act+Industry+Reactions%3A+%27No+One+Will+Grow+a+Crop+That+Might+Be+Illegal+in+November%27+%E2%80%94+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.nutraingredients.com%2FArticle%2F2026%2F02%2F02%2Fproposed-hemp-act-would-create-federal-cbd-pathway-as-hemp-industry-faces-regulatory-crossroads%2F) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) 📰 Source: [https://www.nutraingredients.com/Article/2026/02/02/proposed-hemp-act-would-create-federal-cbd-pathway-as-hemp-industry-faces-regulatory-crossroads/](https://www.nutraingredients.com/Article/2026/02/02/proposed-hemp-act-would-create-federal-cbd-pathway-as-hemp-industry-faces-regulatory-crossroads/) Further Reading Evidence Watch[Regulatory Digest 2026-03-08](https://cedclinic.com/regulatory-digest-2026-03-09/)CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [The Best CBD for Immune Support and Daily Resilience in 2026 | stupidDOPE | Est. 2008](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) Discover top [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) that support immune health and daily resilience, relevant for hemp industry stakeholders and consumers. [Explore CBD Options](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) [The Best CBD for Mental Clarity and Focus in 2026 | stupidDOPE | Est. 2008](https://cedclinic.com/best-cbd-for-mental-clarity-2026-focus-stupiddope/) Learn about CBD products that enhance mental clarity and focus, important for understanding hemp's therapeutic potential. [Learn More](https://cedclinic.com/best-cbd-for-mental-clarity-2026-focus-stupiddope/) [Citywide Art and History Exhibitions – City of Aurora](https://cedclinic.com/citywide-art-and-history-exhibitions-city-of-aurora/) Explore cultural events in Aurora that reflect community engagement, relevant for hemp industry social context. [Discover Events](https://cedclinic.com/citywide-art-and-history-exhibitions-city-of-aurora/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).